---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-011570"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:24:04.463141+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics shareholders reject authorized capital increase; approve stock plan amendment

## Summary
- Proposal 10 to adjust authorized share capital and extend date for capital increase was not approved (37.0M for, 18.8M against).
- Amendment to 2018 Stock Plan approved, adding 1.7M common shares for issuance under the plan.
- Maria Fardis, Ph.D. elected as new board member; all nine incumbent directors re-elected.
- Binding advisory votes on executive compensation approved; frequency of say-on-pay set at one year.
- All other proposals passed, including re-election of auditors and independent voting representative.

## SEC filing metadata
- accession: 0000950170-22-011570
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017022011570/0000950170-22-011570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017022011570/crsp-20220609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-011570
- JSON: https://secwatch.observer/filing/0000950170-22-011570.json
- Plain text: https://secwatch.observer/filing/0000950170-22-011570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.